TrialFrontiers of medicine2021

Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial.

Dongsheng Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.